News Release

Rocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference

Printer Friendly Version View printer-friendly version

NEW YORK--(BUSINESS WIRE)--Feb. 7, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference in New York City. The fireside chat will take place on Wednesday, February 14, 2018, at 2:00 p.m. Eastern Time (ET).

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For more information about Rocket, please visit

Source: Rocket Pharmaceuticals, Inc.

Claudine Prowse, Ph.D.
SVP Corporate Development and IRO
Rocket Pharma, Inc.
The Alexandria Center for Life Science
430 East 29 Street, Suite 1040
New York, NY 10016